Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Jw Pharmaceutical Corporation operates a company patent portfolio within the Biotechnology & Pharmaceuticals sector. Currently, the portfolio has 1 pending office action being managed by 1 distinct examiner. This examiner is COUGHLIN, MATTHEW P, who is responsible for 1 pending office action. The activity is situated within 1 distinct art unit, reflecting a focused prosecution path.
Because there is only 1 pending office action and 1 distinct examiner, the portfolio's current interaction with the patent office is centralized. This structure allows for a direct relationship with the assigned examiner for the pending matter. With 1 pending office action total, the portfolio's current prosecution requirements are concentrated under a single examiner's review. Practitioners should note that the workload is distributed across 1 distinct art unit, suggesting a specific technical focus for the company's pending application at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.4% | +12.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573510 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573510 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE | COUGHLIN, MATTHEW P | 1626 | §112 | Non-Final OA | — | Pending | Dec 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJw Pharmaceutical Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Matthew P Coughlin has the most, with 1 of Jw Pharmaceutical Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.